Nakamura Y, et al. - A 24-month retrospective investigation was carried out in osteoporosis (OP) patients with rheumatoid arthritis (RA) to compare the outcomes of denosumab with or without bisphosphonate (BP) pre-treatment. Findings demonstrated that significantly increased total hip bone mineral density (BMD) [(H-BMD)] was seen at 6 months in those treated with BP versus those with denosumab, while both groups showed significantly increased BMD of the lumbar 1–4 vertebrae (L-BMD) and H-BMD for 24 months. Overall, it was concluded that regardless of BP pre-treatment, denosumab could be a good agent in OP with RA.